SCHEMBL21362090

SCHEMBL21362090

CC(c1cc(O)nnc1Cl)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.42
USP2 O75604 1/20 0.41
TSHR P16473 1/20 0.41
TP53 P04637 3/20 0.37
KMT2A Q03164 2/20 0.37
MAPK1 P28482 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
ALDH1A1 P00352 5/20 0.36
HTT P42858 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
GAA P10253 1/20 0.35
POLB P06746 2/20 0.35
NPC1 O15118 1/20 0.35
KDM4E B2RXH2 1/20 0.35
GLA P06280 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
HPGD P15428 1/20 0.35
ALOX12 P18054 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2896546 0.86 LMNA (0.41) LMNAUSP2TSHRKMT2ANPSR1
SCHEMBL2895355 0.84 USP2 (0.42) LMNAUSP2TSHRTP53KMT2A
SCHEMBL2894014 0.78 LMNA (0.42) LMNAUSP2TSHRTP53KMT2A
SCHEMBL17718345 0.78 EGFR (0.42) LMNAUSP2TSHRKMT2ATDP1
SCHEMBL14870378 0.78 EGFR (0.42) LMNAUSP2TSHRKMT2ATDP1
SCHEMBL21362091 0.75 USP2 (0.41) LMNAUSP2TSHRTP53KMT2A
SCHEMBL4173841 0.75 KMT2A (0.38) LMNAUSP2TSHRKMT2ATDP1
SCHEMBL4173838 0.75 KMT2A (0.38) LMNAUSP2TSHRKMT2ATDP1
SCHEMBL15336892 0.75 KMT2A (0.38) LMNAUSP2TSHRKMT2ATDP1
SCHEMBL4180794 0.74 LMNA (0.39) LMNAUSP2TP53KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) 2019-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF MYC, BRD1, BRD3 LMNA 2333/4885USP2 4208/4885TSHR 4115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.